taranabant taranabant taranabant (codenamed mk-0364) is a cannabinoid receptor type 1 (cb1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. it was discovered by merck & co. taranabantclinical dataroutes ofadministrationoralatc codea08ax (who) legal statuslegal status investigational (failed) identifiers iupac name n--2-methyl-2-propanamide cas number701977-09-5 ypubchem cid11226090chemspider9401143uniix9u622s114comptox dashboard (epa)dtxsid60220464 echa infocard100.207.983 chemical and physical dataformulac27h25clf3n3o2molar mass515.96 g·mol−13d model (jsmol)interactive image smiles c((cc1=cc=c(c=c1)cl)c2=cc=cc(=c2)c#n)nc(=o)c(c)(c)oc3=nc=c(c=c3)c(f)(f)f inchi inchi=1s/c27h25clf3n3o2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23h,14h2,1-3h3,(h,34,35)/t17-,23+/m0/s1key:qlykjcmunuwago-gajhueqpsa-n (verify) in october 2008, merck has stopped its phase iii clinical trials with the drugs due to high level of central nervous system side effects, mainly depression and anxiety.